A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Trial Profile

A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Irritable bowel syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms TARGET-3; Trial 3
  • Sponsors Valeant Pharmaceuticals International
  • Most Recent Events

    • 06 Jun 2017 Results of substudy assessing effect of rifaximin repeat treatment effect on fecal bacterial antibiotic susceptibility, published in the Digestive Diseases and Sciences
    • 09 May 2017 Results assessing effect of repeat rifaximin treatments on IBS-related QOL, presented at the Digestive Disease Week 2017
    • 09 May 2017 Results (n=636) of post hoc analysis assessing sustained IBS response rates and potential baseline predictors for this response, presented at the Digestive Disease Week 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top